Can we select NSCLC patients for immune checkpoint therapy?

10 / 38

Second-Line IO: Does PD-L1 worth?
Brahmer –NEJM 2015 * Borghaei – NEJM 2015 * Herbst – Lancet Oncol 2016 * Rittmeyer – Lancet 2017
Atezolizumab – OAK (P III)
2nd Line, PD-L1 All-comer
Pembro - PD-L1 ≥1%
Nivo - All comers Nivo - All comers
Atezo - All comers